PT - JOURNAL ARTICLE AU - Lydia Breckenridge AU - Yusuf Oni AU - Christina Evans AU - Jason Franck AU - Sharla Wood AU - Meng Xu AU - Erinc Sahin AU - Brian Zacour TI - Determination of ICH-Q3D Elemental Impurity Leachables in Glass Vials by Inductively Coupled Plasma-Mass Spectrometry AID - 10.5731/pdajpst.2021.012655 DP - 2022 Jan 01 TA - PDA Journal of Pharmaceutical Science and Technology PG - pdajpst.2021.012655 4099 - http://journal.pda.org/content/early/2022/10/14/pdajpst.2021.012655.short 4100 - http://journal.pda.org/content/early/2022/10/14/pdajpst.2021.012655.full AB - Container closure systems that are used for packaging pharmaceutical products are required to satisfy numerous safety requirements. Maximum permitted limits on the concentrations of numerous toxic elemental impurities that potentially leach from the packaging are one such requirement. The implementation of ICH-Q3D Guideline for Elemental Impurities, in conjunction with the 2018 publication of USP General Chapters <232> Elemental Impurities - Limits and <233> Elemental Impurities - Procedures, requires a critical risk assessment of all container closure systems to evaluate their contribution of certain elemental impurities to the enclosed drug product. ICH-Q3D has established limits for each specific elemental impurity that considers relevant toxicological data and administration route (oral, parenteral or inhalation) and presents them as permitted daily exposures based on the maximum daily dosage of the final drug product. A study was undertaken to assess the degree of elemental impurity leaching from one type of pharmaceutical glass vial under specific, fixed environmental controls. Multiple buffer systems representing a broad spectrum of possible parenteral drug product formulations were used in the study. Resulting buffer solutions that had been in contact with a single type of glass vial under specific conditions were subsequently analyzed using an inductively coupled plasma-mass spectrometry method developed and validated specifically for the purpose of quantifying elemental impurity leachables in a variety of parenteral formulations. Results indicated that the degree of elemental impurity leachables imparted by the specific type of glass vial evaluated during this study pose no risk to patient safety, regardless of the drug product buffer formulation. Following this evaluation, the ICP-MS method developed for the determination of elemental impurities leachables has been successfully applied to the assessment of elemental impurities in a number of different biological parenteral drug product formulations currently under development. This data can be leveraged for inclusion in elemental impurities component ICH-Q3D risk assessments to satisfy the container closure system contribution.